Free Trial
OTCMKTS:AMAR

Amarillo Biosciences (AMAR) Stock Price, News & Analysis

Amarillo Biosciences logo

About Amarillo Biosciences Stock (OTCMKTS:AMAR)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
6,100 shs
Average Volume
18,253 shs
Market Capitalization
$25.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Amarillo Biosciences, Inc., a healthcare company, engages in the discovery and development of pharmaceutical and biotech products in the United States and Asia. The company operates in three divisions: Pharmaceutical, Medical, and Consumer. The Pharmaceutical division offers low-dose non-injectable interferon (IFN) for the treatment of neoplastic, viral, and fibrotic diseases. The Medical division focuses on medical devices and developing technology to treat metabolism related diseases, such as Type 1 and Type 2 diabetes. The Consumer division provides a range of nutraceutical and food supplement products that utilize a liposomal delivery system. It owns four issued patents related to the low-dose oral delivery of interferon; one patent is for a product promoting oral health; and three patents are associated with treatment of metabolic disorders. The company was incorporated in 1984 and is based in Amarillo, Texas.

Receive AMAR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amarillo Biosciences and its competitors with MarketBeat's FREE daily newsletter.

AMAR Stock News Headlines

If you missed your chance with Tesla...
Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The Future of America's Money." And Silicon Valley insider Jeff Brown says it's about to make early investors RICH. Jeff just filmed a quick presentation with details you should know.
Gufic Biosciences Ltd (GUFI)
See More Headlines

AMAR Stock Analysis - Frequently Asked Questions

Amarillo Biosciences, Inc. (OTCMKTS:AMAR) announced its quarterly earnings results on Wednesday, November, 14th. The company reported ($0.01) earnings per share for the quarter. The company had revenue of $0.02 million for the quarter.

Shares of AMAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Amarillo Biosciences investors own include Fulcrum Therapeutics (FULC), Cerecor (CERC), Neos Therapeutics (NEOS), VIVUS (VVUS), AquaBounty Technologies (AQB), Astria Therapeutics (ATXS) and CymaBay Therapeutics (CBAY).

Company Calendar

Last Earnings
11/14/2018
Today
5/04/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:AMAR
Fax
N/A
Employees
2
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-1,450,000.00
Net Margins
-41,453.98%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$20,000.00
Price / Cash Flow
N/A
Book Value
($0.03) per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$25.24 million
Optionable
Not Optionable
Beta
-0.06

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (OTCMKTS:AMAR) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners